Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious ...

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by ...

The authors write "Suboxone is the brand name of combination of Buprenorphine and Naloxone, manufactured by Indivior, Inc., ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching US$9.39 billion ...

The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...